Do analysts prefer BCLI or NNVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 NanoViricides 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has stronger valuation & earnings, BCLI or NNVC?

NanoViricides is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A NanoViricides N/A N/A -$8.29M -$0.43 N/A

Is BCLI or NNVC more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% NanoViricides N/A -87.90% -78.69%

Do analysts prefer CPHI or BCLI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Does the media refer more to CPHI or BCLI?

In the previous week, Brainstorm Cell Therapeutics had 3 more articles in the media than China Pharma. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Brainstorm Cell Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend BCLI or VIRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation & earnings, BCLI or VIRI?

Virios Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.64 N/A Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A

Is BCLI or VIRI more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Virios Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% Virios Therapeutics N/A -130.33% -115.00%

Do analysts recommend BCLI or ABVC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is BCLI or ABVC more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity. Company Net Margins Return on Equity Return on Assets Brainstorm Cell Therapeutics N/A N/A -519.50% ABVC BioPharma N/A -62.46% -39.99%

Do analysts rate ALGS or BCLI?

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 621.11%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aligos Therapeutics is more favorable than Brainstorm Cell Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aligos Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Brainstorm Cell Therapeutics 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Brainstorm Cell Therapeutics (BCLI) Competitors

$0.79 +0.02 (+3.00%)

As of 02:44 PM Eastern

Compare

BCLI vs. NNVC, CPHI, VIRI, ABVC, and ALGS

Should you buy Brainstorm Cell Therapeutics stock or one of its competitors? MarketBeat compares Brainstorm Cell Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Brainstorm Cell Therapeutics include NanoViricides (NNVC), China Pharma (CPHI), Virios Therapeutics (VIRI), ABVC BioPharma (ABVC), and Aligos Therapeutics (ALGS). These companies are all part of the "pharmaceutical products" industry.

How does Brainstorm Cell Therapeutics compare to NanoViricides?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and NanoViricides (NYSE:NNVC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations, media sentiment and profitability.

Brainstorm Cell Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, NanoViricides has a beta of 1.66, suggesting that its stock price is 66% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Brainstorm Cell Therapeutics' return on equity of 0.00% beat NanoViricides' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
NanoViricides	N/A	-87.90%	-78.69%

NanoViricides is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A

In the previous week, Brainstorm Cell Therapeutics had 4 more articles in the media than NanoViricides. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 0 mentions for NanoViricides. Brainstorm Cell Therapeutics' average media sentiment score of 0.00 equaled NanoViricides'average media sentiment score.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Neutral
NanoViricides	Neutral

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 10.3% of NanoViricides shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 3.6% of NanoViricides shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

NanoViricides beats Brainstorm Cell Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to China Pharma?

China Pharma (NYSE:CPHI) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends.

China Pharma has higher revenue and earnings than Brainstorm Cell Therapeutics. China Pharma is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
China Pharma	$3.99M	8.57	-$3.08M	-$0.55	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A

In the previous week, Brainstorm Cell Therapeutics had 3 more articles in the media than China Pharma. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 1 mentions for China Pharma. China Pharma's average media sentiment score of 0.00 equaled Brainstorm Cell Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
China Pharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
China Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 6.4% of China Pharma shares are held by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to China Pharma's net margin of -85.56%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat China Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
China Pharma	-85.56%	-63.93%	-31.42%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

China Pharma has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

Summary

Brainstorm Cell Therapeutics beats China Pharma on 7 of the 12 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Virios Therapeutics?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat Virios Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
Virios Therapeutics	N/A	-130.33%	-115.00%

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 9.1% of Virios Therapeutics shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by company insiders. Comparatively, 12.2% of Virios Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Virios Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A

In the previous week, Brainstorm Cell Therapeutics had 4 more articles in the media than Virios Therapeutics. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 0 mentions for Virios Therapeutics. Virios Therapeutics' average media sentiment score of 0.75 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Virios Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Neutral
Virios Therapeutics	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Brainstorm Cell Therapeutics has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Virios Therapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

Summary

Virios Therapeutics beats Brainstorm Cell Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to ABVC BioPharma?

Brainstorm Cell Therapeutics (NASDAQ:BCLI) and ABVC BioPharma (NASDAQ:ABVC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat ABVC BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%
ABVC BioPharma	N/A	-62.46%	-39.99%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. Comparatively, 11.4% of ABVC BioPharma shares are held by institutional investors. 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Comparatively, 19.0% of ABVC BioPharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ABVC BioPharma has higher revenue and earnings than Brainstorm Cell Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A
ABVC BioPharma	$510K	69.84	-$7.91M	-$0.40	N/A

In the previous week, Brainstorm Cell Therapeutics had 4 more articles in the media than ABVC BioPharma. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 0 mentions for ABVC BioPharma. ABVC BioPharma's average media sentiment score of 1.87 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that ABVC BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Brainstorm Cell Therapeutics	Neutral
ABVC BioPharma	Very Positive

Brainstorm Cell Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market. Comparatively, ABVC BioPharma has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market.

Summary

ABVC BioPharma beats Brainstorm Cell Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Brainstorm Cell Therapeutics compare to Aligos Therapeutics?

Aligos Therapeutics (NASDAQ:ALGS) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and institutional ownership.

Brainstorm Cell Therapeutics has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than Brainstorm Cell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$2.19M	15.09	-$24.19M	-$8.69	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.64	N/A

Brainstorm Cell Therapeutics has a net margin of 0.00% compared to Aligos Therapeutics' net margin of -1,919.68%. Brainstorm Cell Therapeutics' return on equity of 0.00% beat Aligos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-1,919.68%	-139.47%	-90.88%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

Aligos Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.3, suggesting that its stock price is 70% less volatile than the broader market.

60.4% of Aligos Therapeutics shares are owned by institutional investors. Comparatively, 14.3% of Brainstorm Cell Therapeutics shares are owned by institutional investors. 7.8% of Aligos Therapeutics shares are owned by company insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Brainstorm Cell Therapeutics had 4 more articles in the media than Aligos Therapeutics. MarketBeat recorded 4 mentions for Brainstorm Cell Therapeutics and 0 mentions for Aligos Therapeutics. Aligos Therapeutics' average media sentiment score of 1.22 beat Brainstorm Cell Therapeutics' score of 0.00 indicating that Aligos Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aligos Therapeutics	Positive
Brainstorm Cell Therapeutics	Neutral

Aligos Therapeutics presently has a consensus target price of $38.50, indicating a potential upside of 621.11%. Given Aligos Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Aligos Therapeutics is more favorable than Brainstorm Cell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Brainstorm Cell Therapeutics	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aligos Therapeutics beats Brainstorm Cell Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Brainstorm Cell Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BCLI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BCLI vs. The Competition

Export

Metric	Brainstorm Cell Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$8.75M	$3.34B	$6.43B	$12.49B
Dividend Yield	N/A	2.37%	2.69%	5.22%
P/E Ratio	-0.24	18.86	23.86	24.42
Price / Sales	N/A	320.30	521.12	117.04
Price / Cash	N/A	110.40	41.27	57.13
Price / Book	-0.58	6.81	10.04	6.74
Net Income	-$11.62M	$24.09M	$3.56B	$337.03M
7 Day Performance	10.71%	-2.39%	-0.81%	0.24%
1 Month Performance	N/A	N/A	N/A	-1.67%
1 Year Performance	-29.19%	48.97%	28.80%	34.36%

Brainstorm Cell Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BCLI Brainstorm Cell Therapeutics	0.0979 of 5 stars	$0.79 +3.0%	N/A	-28.7%	$8.75M	N/A	N/A	40	Gap Up
NNVC NanoViricides	0.1805 of 5 stars	$1.61 -4.5%	N/A	+2.7%	$34.74M	N/A	N/A	20
CPHI China Pharma	N/A	$0.83 +8.3%	N/A	-46.0%	$33.76M	$3.99M	N/A	250
VIRI Virios Therapeutics	N/A	$1.70 +0.6%	N/A	-68.3%	$32.74M	N/A	N/A	5	Gap Up
ABVC ABVC BioPharma	0.7875 of 5 stars	$1.25 -8.1%	N/A	-22.4%	$32.50M	N/A	N/A	30	Positive News Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BCLI) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. NNVC, CPHI, VIRI, ABVC, and ALGS

How does Brainstorm Cell Therapeutics compare to NanoViricides?

Summary

How does Brainstorm Cell Therapeutics compare to China Pharma?

Summary

How does Brainstorm Cell Therapeutics compare to Virios Therapeutics?

Summary

How does Brainstorm Cell Therapeutics compare to ABVC BioPharma?

Summary

How does Brainstorm Cell Therapeutics compare to Aligos Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Brainstorm Cell Therapeutics (BCLI) Competitors

BCLI vs. NNVC, CPHI, VIRI, ABVC, and ALGS

How does Brainstorm Cell Therapeutics compare to NanoViricides?

Which has more volatility & risk, BCLI or NNVC?

Do analysts prefer BCLI or NNVC?

Is BCLI or NNVC more profitable?

Which has stronger valuation & earnings, BCLI or NNVC?

Does the media prefer BCLI or NNVC?

Do insiders & institutionals hold more shares of BCLI or NNVC?

Summary

How does Brainstorm Cell Therapeutics compare to China Pharma?

Which has preferable earnings and valuation, CPHI or BCLI?

Does the media refer more to CPHI or BCLI?

Do analysts prefer CPHI or BCLI?

Do insiders and institutionals have more ownership in CPHI or BCLI?

Is CPHI or BCLI more profitable?

Which has more risk and volatility, CPHI or BCLI?

Summary

How does Brainstorm Cell Therapeutics compare to Virios Therapeutics?

Is BCLI or VIRI more profitable?

Do insiders and institutionals have more ownership in BCLI or VIRI?

Which has stronger valuation & earnings, BCLI or VIRI?

Does the media refer more to BCLI or VIRI?

Do analysts recommend BCLI or VIRI?

Which has more volatility and risk, BCLI or VIRI?

Summary

How does Brainstorm Cell Therapeutics compare to ABVC BioPharma?

Is BCLI or ABVC more profitable?

Do analysts recommend BCLI or ABVC?

Do insiders & institutionals have more ownership in BCLI or ABVC?

Which has better earnings and valuation, BCLI or ABVC?

Does the media prefer BCLI or ABVC?

Which has more volatility & risk, BCLI or ABVC?

Summary

How does Brainstorm Cell Therapeutics compare to Aligos Therapeutics?

Which has stronger valuation and earnings, ALGS or BCLI?

Is ALGS or BCLI more profitable?

Which has more volatility & risk, ALGS or BCLI?

Do institutionals & insiders have more ownership in ALGS or BCLI?

Does the media favor ALGS or BCLI?

Do analysts rate ALGS or BCLI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCLI vs. The Competition

Brainstorm Cell Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools